IgE based therapeutics are an emerging modality in cancer treatment

Targeting human diseases using antibodies is a rapidly evolving area of research that could transform healthcare. Currently, various diseases, including cancer, are treated by immunotherapy using the IgG class of antibodies. Recently, efforts have been made to broaden the range of available treatments by utilizing the distinct features of other antibody classes. Notably, the IgE antibody has shown encouraging results in restricting tumor growth with the first therapeutic antibody MOv18 IgE showing promising results in clinical trials, with good tolerance and safety in patients with ovarian carcinoma. However, several challenges remain. This review discusses recent developments in the engineering of the IgE antibody for cancer therapeutics, focusing on improving manufacturability and reducing immunogenicity by modifying IgE glycosylation complexity. Additionally, bispecific formats of IgE are being established to engage multiple targets simultaneously. Building on the recent studies in these areas, the ongoing research on IgE therapeutics has provided potential opportunities for clinical development and as a therapy in the future. These outcomes and advancements, along with a better clinical safety profile, may increase the treatment options for cancer patients in the future together with existing and approved IgG therapies.